Effect of coenzyme q10 on myopathic symptoms in patients treated with statins
- PMID: 17493470
- DOI: 10.1016/j.amjcard.2006.12.063
Effect of coenzyme q10 on myopathic symptoms in patients treated with statins
Abstract
Treatment of hypercholesterolemia with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) is effective in the primary and secondary prevention of cardiovascular disease. However, statin use is often associated with a variety of muscle-related symptoms or myopathies. Myopathy may be related in part to statin inhibition of the endogenous synthesis of coenzyme Q10, an essential cofactor for mitochondrial energy production. The aim of this study is to determine whether coenzyme Q10 supplementation would reduce the degree of muscle pain associated with statin treatment. Patients with myopathic symptoms were randomly assigned in a double-blinded protocol to treatment with coenzyme Q10 (100 mg/day, n = 18) or vitamin E (400 IU/day, n = 14) for 30 days. Muscle pain and pain interference with daily activities were assessed before and after treatment. After a 30-day intervention, pain severity decreased by 40% (p <0.001) and pain interference with daily activities decreased by 38% (p <0.02) in the group treated with coenzyme Q10. In contrast, no changes in pain severity (+9%, p = NS) or pain interference with daily activities (-11%, p = NS) was observed in the group treated with vitamin E. In conclusion, results suggest that coenzyme Q10 supplementation may decrease muscle pain associated with statin treatment. Thus, coenzyme Q10 supplementation may offer an alternative to stopping treatment with these vital drugs.
Comment in
-
Statins, coenzyme Q10, and cachexia: what's the link?Am J Cardiol. 2007 Nov 1;100(9):1497-8. doi: 10.1016/j.amjcard.2007.07.007. Epub 2007 Jul 25. Am J Cardiol. 2007. PMID: 17950821 No abstract available.
-
Coenzyme Q10 Deficiency.Dtsch Arztebl Int. 2016 May 13;113(19):344-5. doi: 10.3238/arztebl.2016.0344b. Dtsch Arztebl Int. 2016. PMID: 27232365 Free PMC article. No abstract available.
Similar articles
-
Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study.Med Sci Monit. 2014 Nov 6;20:2183-8. doi: 10.12659/MSM.890777. Med Sci Monit. 2014. PMID: 25375075 Free PMC article. Clinical Trial.
-
Coenzyme Q10 and statin-related myopathy.Drug Ther Bull. 2015 May;53(5):54-6. doi: 10.1136/dtb.2015.5.0325. Drug Ther Bull. 2015. PMID: 25977402
-
HMG-CoA reductase inhibitors and coenzyme Q10.Cardiol Rev. 2005 Mar-Apr;13(2):76-9. doi: 10.1097/01.crd.0000154790.42283.a1. Cardiol Rev. 2005. PMID: 15705257 Review.
-
Effect of coenzyme Q10 supplementation on statin-induced myalgias.Am J Cardiol. 2012 Aug 15;110(4):526-9. doi: 10.1016/j.amjcard.2012.04.026. Epub 2012 May 18. Am J Cardiol. 2012. PMID: 22608359 Clinical Trial.
-
The role of coenzyme Q10 in statin-associated myopathy: a systematic review.J Am Coll Cardiol. 2007 Jun 12;49(23):2231-7. doi: 10.1016/j.jacc.2007.02.049. J Am Coll Cardiol. 2007. PMID: 17560286 Review.
Cited by
-
Ferroptosis as an emerging target in sickle cell disease.Curr Res Toxicol. 2024 Jun 18;7:100181. doi: 10.1016/j.crtox.2024.100181. eCollection 2024. Curr Res Toxicol. 2024. PMID: 39021403 Free PMC article.
-
Comparison of Coenzyme Q10 (Ubiquinone) and Reduced Coenzyme Q10 (Ubiquinol) as Supplement to Prevent Cardiovascular Disease and Reduce Cardiovascular Mortality.Curr Cardiol Rep. 2023 Dec;25(12):1759-1767. doi: 10.1007/s11886-023-01992-6. Epub 2023 Nov 16. Curr Cardiol Rep. 2023. PMID: 37971634 Free PMC article. Review.
-
Coenzyme Q10 Supplementation in Statin Treated Patients: A Double-Blinded Randomized Placebo-Controlled Trial.Antioxidants (Basel). 2022 Aug 29;11(9):1698. doi: 10.3390/antiox11091698. Antioxidants (Basel). 2022. PMID: 36139772 Free PMC article.
-
Coenzyme Q nanodisks counteract the effect of statins on C2C12 myotubes.Nanomedicine. 2021 Oct;37:102439. doi: 10.1016/j.nano.2021.102439. Epub 2021 Jul 10. Nanomedicine. 2021. PMID: 34256063 Free PMC article.
-
Effect of statin treatment in obese selenium-supplemented mice lacking selenocysteine lyase.Mol Cell Endocrinol. 2021 Aug 1;533:111335. doi: 10.1016/j.mce.2021.111335. Epub 2021 May 27. Mol Cell Endocrinol. 2021. PMID: 34052303 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
